Third People's Hospital of Hangzhou

Running trials

• Not yet recruiting

  Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma

  NCT07575724· Phase 2· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Not yet recruiting

  A Phase 3 Study of Povorcitinib Phosphate in Chinese Adults With Nonsegmental Vitiligo

  NCT07865312· Phase 3· Dermavon Holdings Limited· Source

• Recruiting

  A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

  NCT07533019· Phase 2· Eli Lilly and Company· Source

• Not yet recruiting

  A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis

  NCT07465120· Phase 2· Dermavon Holdings Limited· Source

• Not yet recruiting

  A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis

  NCT07432854· Phase 2/3· Dermavon Holdings Limited· Source

• Not yet recruiting

  Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome

  NCT07352488· Henan University of Traditional Chinese Medicine· Source

• Active, not recruiting

  A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis

  NCT07321951· Phase 2· Guangdong Hengrui Pharmaceutical Co., Ltd· Source

• Recruiting

  A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

  NCT06807281· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of Zasocitinib in Adults With Nonsegmental Vitiligo

  NCT07108283· Phase 2· Takeda· Source

• Recruiting

  Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

  NCT07116967· Phase 3· Bristol-Myers Squibb· Source

• Active, not recruiting

  A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

  NCT06807268· Phase 3· Pfizer· Source

• Recruiting

  ICP-332 in Subjects With Non-segmental Vitiligo

  NCT07047612· Phase 2/3· Beijing InnoCare Pharma Tech Co., Ltd.· Source

• Not yet recruiting

  Tranilast Vs. Steroids to Prevent Esophageal Stricture (TAPES) After Endoscopic Resection for Superficial Neoplasms

  NCT06643689· Phase 2· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis

  NCT06775860· Phase 3· Beijing InnoCare Pharma Tech Co., Ltd.· Source

• Active, not recruiting

  A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

  NCT06118411· Phase 3· AbbVie· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atopic dermatitis (eczema)3 recruiting
• Vitiligo3 recruiting
• Psoriasis2 recruiting
• Asthma1 recruiting
• Childhood cancers1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Sarcoma1 recruiting

Closed trials

• Completed

  To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

  NCT06552520· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

  NCT06700499· Phase 2· Akeso· Source

• Completed

  Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06477237· Phase 3· Huabo Biopharm Co., Ltd.· Source

• Completed

  Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo

  NCT07181187· Phase 2· Minghui Pharmaceutical (Hangzhou) Ltd· Source

• Completed

  A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

  NCT05975268· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  The PRECISION-T2D Study: Precision Nutrition Study for Type 2 Diabetes

  NCT05885828· Westlake University· Source

• Completed

  HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.

  NCT07712705· Phase 3· Newsoara Biopharma Co., Ltd.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

  NCT05531682· Phase 2· Huabo Biopharm Co., Ltd.· Source

• Completed

  A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis

  NCT06035354· Phase 1/2· Akeso· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Vitiligo16 works · 6 trials
• Alopecia areata6 works · 0 trials